Cabergoline

ATC CodeG02CB03, N04BC06
CAS number81409-90-7
PUB number54746
Drugbank IDDB00248
Empirical formulaC26H37N5O2
Molar mass (g·mol−1)451,6043
Physical statesolid
Melting point (°C)102-204

Basics

Cabergoline is a dopamine receptor agonist, which means that it mimics the effect of the neurotransmitter dopamine. In human medicine, the drug is used on the one hand to treat neurological diseases such as Parkinson's disease or restless legs syndrome, and on the other hand to treat gynecological diseases involving weaning or prolactin excess (hormone that forms breast milk).

Pharmacology

Pharmacodynamics

The drug stimulates centrally located dopamine receptors, mainly the D2 and D3 receptor subtypes, with postsynaptic D2 stimulation (downstream of the synaptic cleft) responsible for the antiparkinsonian effects and presynaptic D2 stimulation (upstream of the synaptic cleft) responsible for the neuron-protective effects.
Cabergoline's dopamine-like effects inhibit prolactin production in the pituitary gland.

Pharmacokinetics

Cabergoline is metabolized primarily in the liver by cleavage of the acylurea bond. The enzyme responsible for metabolism has not yet been identified; the cytochrome P450 enzyme plays only a minimal role.
The estimated half-life is up to 69 hours. The drug is excreted mainly in the feces.

Drug Interactions

Because of its dopamine receptor-stimulating effects, cabergoline should not be used together with dopamine receptor-inhibiting drugs (e.g., metoclopramide, phenothiazines, butyrophenones, thioxanthenes).
To avoid elevated cabergoline plasma levels, the drug should not be combined with macrolide antibiotics, such as erythromycin.

Toxicity

Side effects

Often treatment with Cabergoline leads to swelling of arms and/or legs, valvular changes resulting in inflammation or fluid accumulation in the pericardium.
Furthermore, side effects such as nausea, headache or dizziness may occur.

Toxicological data

In case of overdose, nasal congestion, circulatory collapse or hallucinations may be expected.
LD50 (rat, oral): 420 mg/kg

Markus Falkenstätter, BSc

Markus Falkenstätter, BSc

Mag. pharm. Stefanie Lehenauer

Mag. pharm. Stefanie Lehenauer



Logo

Your personal medication assistant

Drugs

Browse our extensive database of medications from A-Z, including effects, side effects, and dosage.

Substances

All active ingredients with their effects, applications, and side effects, as well as the medications they are contained in.

Diseases

Symptoms, causes, and treatments for common diseases and injuries.

Social media

The presented content does not replace the original package insert of the medication, especially regarding the dosage and effects of individual products. We cannot assume liability for the accuracy of the data, as the data has been partially converted automatically. Always consult a doctor for diagnoses and other health-related questions.

© medikamio